

FREE

LIVE AND INTERACTIVE SATELLITE BROADCAST

Designed for physicians, pharmacists, psychologists, and nurses

Beyond Psychosis: Broad Spectrum Use of the Atypical Antipsychotics

August 26, 2003

This one hour activity will broadcast at:

Eastern: 12 p.m.- 1 p.m. and 3 p.m.- 4 p.m.

Central: 11 a.m.- 12 p.m. and 2 p.m.- 3 p.m.

Mountain: 10 a.m.- 11 a.m. and 1 p.m.- 2 p.m.

Pacific: 9 a.m.- 10 a.m. and 12 p.m.- 1 p.m.

Presenter:

Andrew Cutler, MD
President
Core Research
Winter Park, Florida

Moderator:

Henry Nasrallah, MD
Associate Dean, Professor of Psychiatry,
Neurology and Neuroscience
Director, Schizophrenia Research Program
University of Cincinnati College of Medicine

Learning Objectives:

At the end of this educational activity, participants should be able to:

1. Discuss the reasons why atypical antipsychotics are generally safer and better tolerated than older antipsychotic medicines, which shifts the risk/benefit ratio in favor of broader use
2. Explain the emerging data that suggests that the atypical antipsychotics have efficacy in a broad range of psychiatric syndromes, such as mania, depression, and anxiety
3. Summarize how atypical antipsychotics may be a useful treatment modality for a broad range of non-psychotic conditions

Description:

As clinicians have become more comfortable with the use of atypical antipsychotics in the treatment of psychosis, the potential for the use of these drugs in other conditions has become a focus of interest. Prescribers have found utility in these off-label uses despite a relative lack of data. Unmet needs and opportunities exist for patients who either have inadequate responses or tolerability issues with more established medicines. Also driving this trend is the fact that the atypicals are generally safer and better tolerated than the older antipsychotic medications. The atypicals have demonstrated efficacy in treating a wide range of symptoms in addition to their primary indication of schizophrenia, such as mania, depression, anxiety, hostility and aggression. In addition, clinicians are increasingly using these medicines for conditions such as dementia, autism, developmental delay/mental retardation and personality disorders. Due to their apparent broad spectrum effectiveness and relative safety, it is rational to consider using the atypicals for other conditions, such as PTSD, borderline personality disorder, OCD, ADHD and GAD. These conditions manifest symptoms such as affective instability, anxiety and impulsivity that may be amenable to treatment with the atypicals. Preliminary data on the use of atypical antipsychotics in non-psychotic psychiatric conditions will be presented and analyzed. Future directions for clinical treatment and research will also be discussed.

ACCREDITATION STATEMENTS/CREDIT DESIGNATION

Distance Learning Network, Inc. has been approved by the American Psychological Association (APA) as a provider of continuing education for psychologists. Distance Learning Network maintains responsibility for the program. The participant will be awarded 1 contact hour of credit for attendance and completion of supplemental materials.

Distance Learning Network, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Distance Learning Network designates this educational activity for a maximum of 1 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those hours of credit he/she actually spent in the educational activity.



The University of Florida College of Pharmacy is accredited by the American Council on Pharmaceutical Education as a provider of continuing pharmaceutical education. This program is approved for 1 contact hour (0.1 CEU's) in states that recognize ACPE. To receive credit you must attend the entire session and complete the evaluation form. The University of Florida College of Pharmacy will provide statements of Continuing Education Credit within 4 weeks after the session. 012-999-03-096-L01



Distance Learning Network has been approved as a provider of continuing education in nursing by the Utah Nurses Association, which is accredited as an approver of continuing education in nursing by the American Nurses Credentialing Center's Commission on Accreditation. The participant will be awarded 1.2 contact hours of credit for attendance and completion of supplemental materials.

To register call 1-800-326-9166 or visit www.dlnetwork.com

Site Name: _____

Address: _____

City: _____ State: _____ Zip: _____

Contact: _____ Phone: _____

Fax: _____ Email: _____



Distance Learning Network

COMMERCIAL SUPPORT

This activity is supported by an educational grant to Distance Learning Network from AstraZeneca